Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125209 · ClinicalTrials.gov registry record
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
A clinical trial of Ovarian Cancer and Cognitive Change, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 18
- Enrollment target
- 1
- Study location
NCT07125209 is a study of Ovarian Cancer and Cognitive Change that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 18 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07125209, a study of Ovarian Cancer and Cognitive Change, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approximately 10 months.
Conditions Studied
Interventions
- OTHER Patient Reported Outcomes Assessment
- OTHER Cognitive and General Health Assessments
Study Locations (1)
Wisconsin
- UW Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07125209
The ClinicalTrials.gov registry entry for NCT07125209 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Patient Reported Outcomes Assessment is the first listed.
NCT07125209 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07125209 about?
NCT07125209 is a clinical study titled "Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer". The purpose of this research is to assess several components of cognition in patients recently diagnosed with advanced epithelial ovarian cancer and who will be undergoing neoadjuvant chemotherapy for treatment of the cancer. 18 participants will be enrolled and can expect to be on study for approxi...
What is the current status of trial NCT07125209?
This trial is currently recruiting. The enrollment target is 18 participants. The study started on 2026-03. Estimated completion is 2027-12.
What conditions does trial NCT07125209 study?
This clinical trial studies the following conditions: Ovarian Cancer, Cognitive Change.
What interventions are being tested in trial NCT07125209?
The interventions under investigation include: Patient Reported Outcomes Assessment (OTHER), Cognitive and General Health Assessments (OTHER).
Who is sponsoring clinical trial NCT07125209?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07125209 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.